^
    Back
    Association details:
    Biomarker:TFE3 translocation
    Cancer:Renal Cell Carcinoma
    Drug:Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)

    Excerpt:
    ...including chromophobe renal cell carcinoma, sarcomatoid renal cell carcinoma, Xp11 translocation (TFE3+ IHC) carcinoma, other renal carcinoma NOS...
    Trial ID:
    UNICAB
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GU 2021
    Title:

    Efficacy of cabozantinib in advanced MiT family translocation renal cell carcinomas (TRCC).

    Published date:
    02/08/2021
    Excerpt:
    We performed a multicentre, retrospective, international cohort study of patients with TRCC treated with cabozantinib...24 were evaluable for response and were included in this study (21 with TFE3 and 3 with TFEB translocations)...The proportion of patients who achieved an objective response was 16.6%, including 1 complete response and 3 partial responses. For 11 (45.8%) patients, stable disease was the best response....This real-world study provides evidence supporting activity of cabozantinib in TRCC, with more durable responses to therapy...
    DOI:
    10.1200/JCO.2021.39.6_suppl.274